a molecule being newer does not make it better

extrapolation from the published trials to what people do here is the biggest weakness in the channel and it should be said out loud, its in my notes somewhere

nobody here is your clinician and this channel is the last place that should be treated as one, this channel is not a source

will try that, phase 2, thats it

the purity spread across lots worries me more than the molecule does, i would want phase three first

logging this properly, so sourcing is thinner here because fewer suppliers make it and the ones that do make less of it, phase two is all we have

baseline panel done so why does this channel talk in weeks rather than in steps, first time doing this

triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history, phase two is all we have

hope it settles, because the base is thin

is the glucagon arm supposed to be doing something noticeable or is that below the threshold

with a spreadsheet

interested and cautious

the published data is phase two, which is a very different evidence base from the licensed compounds

being pedantic about the data here the triple agonist mechanism is well described. what any individual feels is not attributable to a mechanism

habits not evidence

holding low deliberately